Challenges in initiating and conducting personalized cancer therapy trials: Perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial

Keyphrases

• Clinical Trials 100%
• Personalized Cancer Therapy 100%
• Innovative Network 100%
• Therapeutic Agents 50%
• Precision Medicine 50%
• France 50%
• Treatment Decisions 50%
• In Cancer 50%
• Patients with Cancer 50%
• Targeted Therapy 50%
• Molecular Analysis 50%
• Patient Care 50%
• Targeted Therapeutics 50%
• Canada 50%
• Therapy Efficacy 50%
• Cancer Center 50%
• Off-label Use 50%
• Pharmaceutical Companies 50%
• Omics Technologies 50%
• Multinational Trial 50%
• Access to Drugs 50%
• Internal Mechanism 50%
• Transcriptomic Assay 50%
• Genomic Assay 50%
• McGill University 50%
• Regulatory Hurdles 50%

Medicine and Dentistry

• Malignant Neoplasm 100%
• Cancer Therapy 100%
• Clinical Trial 66%
• Personalized Medicine 33%
• Drug Therapy 33%
• Diagnosis 33%
• Targeted Therapy 33%
• Tamsulosin 33%
• Transcriptomics 33%
• Off-Label Use 33%
• Biopharmaceuticals 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Malignant Neoplasm 100%
• Clinical Trial 33%
• Off-Label Use 16%
• Tamsulosin 16%